Freedom of Information Act 2000 - Request Reference FoI/20/072
Adalimumab

Request details

1.

	Rheumatology	Dermatology	Gastroenterology
Is the branded biosimilar AMGEVITA listed on your formulary?			

2. Please complete the number of patients prescribed with the following products in the last 12 months within the Rheumatology, Dermatology and Gastroenterology departments:

Product/place in the adalimumab therapy pathway*	Rheumatology	Dermatology	Gastroenterology
AMGEVITA first-line			
AMGEVITA second-line			
HUMIRA first-line			
HUMIRA second-line			
HYRIMOZ first-line			
IMRALDI first-line			

*How many patients receive the listed therapies as a first or second treatment once they reach the biologic/biosimilar part of their treatment pathway. For example, according to the NICE Pathway, psoriasis patients should receive topical therapy, then systemic non-biological therapy, then systemic biological therapy. We would like to know which therapies are received first and second in the biological therapy part of the pathway.

3. Please complete the table below:

Question	Department					
	Dermatology	Rheumatology			Gastroenterology	
	Psoriasis	Psoriatic arthritis	Rheumatoid arthritis	Ankylosing spondylitis	Crohn's disease	Ulcerative colitis
Are any local						

guidelines followed that recommend earlier use of anti-TNF biologics/ biosimilars in the treatment pathway?						
Are there occasions where patients can receive adalimumab outside of NICE/SMC/AW MSG/National criteria?						

4. **What is the contractual agreement for seeing and treating patients with anti-TNF biologics between you and your referring CCGs/Health Boards?**

Contractual agreement	Yes/No
Block contracts	
Fixed price on a patient-by-patient basis	

Response details

After considering your request, Cardiff and Vale University Health Board (the UHB) believes that Section 14 of the Freedom of Information Act 2000 applies in this instance and is refusing your request. The reason for relying on this exemption is set out below.

Under Section 14 of the Act, an organisation does not have to respond to a request if the information being sought is repeated or vexatious. The UHB has applied this exemption to your request as the information you are seeking represents a repeated request and the UHB has previously complied with the same request for information. Under our Section 16 obligation to advise and assist, I can confirm that the UHB are unable to identify first-line or second-line prescribing. However, please find attached further information in relation to the the pathways for rheumatoid arthritis (most common disease using biologics within rheumatology) and psoriasis. Where “anti-TNF” is quoted in rheumatoid arthritis this is invariably a biosimilar adalimumab unless there is a strong reason for it not to be (rare).